Introduction
Chronic myeloid leukemia (CML) is characterized by uncontrolled expansion of myeloid cells and the BCR/ABL1 oncogene. 1, 2 The BCR/ABL1 tyrosine-kinase inhibitor (TKI) imatinib is considered a ´gold-standard´ of treatment of patients with newly diagnosed CML. [3] [4] [5] [6] However, resistance against imatinib may occur, often in association with BCR/ABL1 mutations. [5] [6] [7] Treatment of TKI-resistant CML is an emerging challenge. For these patients, more effective TKIs, including nilotinib, dasatinib, bosutinib and ponatinib, have been developed and are successfully used in clinical trials and daily practice. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Novel TKIs also exert major anti-leukemic activity in freshly diagnosed patients with CML, with higher rates of complete cytogenetic (CCyR) and molecular (MMR) responses compared to imatinib. [17] [18] [19] [20] Superior efficacy of these TKIs may result from stronger effects on BCR/ABL1, effects on various BCR/ABL1-mutants, and suppression of additional drug-targets. [21] [22] [23] [24] [25] However, several targets are also expressed in non-hematopoietic cells and may therefore be responsible for nonhematologic adverse events (AEs). Whereas in many cases, side effects are mild and manageable [12] [13] [14] [15] [16] [17] [18] [19] [20] , some of these patients develop severe organ damage.
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One emerging type of clinically relevant AEs in patients receiving second-or third-generation BCR/ABL1 TKIs are vascular AEs (VAEs).
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The unique profiles of AEs seen with BCR/ABL1 TKIs A unique spectrum of AEs has been reported for each TKI used to treat CML (Supplemental Table S1 ). In dasatinib-treated patients, the occurrence of pleural and/or pericardial effusions is an issue.
13,18,26-28 Several other non-hematologic AEs have also been described for dasatinib. 13, 27, 33 The frequency of AEs is lower in patients receiving 100 mg dasatinib once daily compared to higher doses. 28, 34, 35 However, even at 100 mg/day, pleural effusions may develop. 28, 36 Recently, pulmonary hypertension has been reported in patients treated with dasatinib (Supplemental Table S1 ). [37] [38] [39] However, the frequency of this AE is low 37-39 and the same holds true for arterial occlusive events, although VAEs have been reported (Supplemental Table S1 ).
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Nilotinib-treated patients may develop elevated pancreatic enzymes, an increase in serum bilirubin and/or an increase in fasting glucose levels. 12, 17, 29, 41 Moreover, the cholesterol level may increase. 42, 43 Other non-hematologic AEs include constipation, diarrhea and a folliculitis-like skin rash (Supplemental Table S1 ).
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During the past few years more and more data suggest that severe peripheral arterial occlusive disease (PAOD) and other cardiovascular events develop in patients receiving nilotinib. [29] [30] [31] [44] [45] [46] [47] Several of these patients suffer from a rapidly progressive form of PAOD. [29] [30] [31] Unfortunately, PAODs were also found to accumulate over time, and were recorded not only in patients in whom cardiovascular risk factors were present, but sometimes also in younger patients Table S1 ).
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Reported frequencies of VAEs in TKI-treated patients with CML of patients with documented VAEs remained low (<5%). However, in first prospective analyses, the frequency of VAEs in these trials is again higher and increases over time. There is also some indication that TKIs trigger VAEdevelopment in a dose-dependent manner. Likewise, nilotinib-treated patients may be at higher risk to develop VAEs when receiving 2x400 mg/day compared to a lower dose (2x300 mg/day).
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The frequency of all VAEs in patients treated with ponatinib in the PACE trial was 8.9% after 11 months and 17.1% after 24 months (Table 1) 
Why did we initially overlook VAEs in our patients with CML?
A number of different factors may explain why we did initially overlook the VAEtriggering potential of nilotinib and ponatinib (Table 2 ). This is an important issue and needs attention in the era of TKI therapy. Specific factors and potential explanations are discussed in the Supplemental Appendix. Table S2 ).
Risk factors predisposing for the development of VAEs
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There are several other factors that have to be considered in these patients. One such risk factor is the dose of the TKI. Notably, clinically relevant AEs, including
VAEs, appear to increase in frequency with higher TKI-doses. 27, 34, 35, 53, 65 In other words, it may well be that the rates of severe VAEs can be decreased substantially by lowering the TKI-dose. 53 In addition, the risk may decrease with shorter exposure-times. Another important point is previous therapy. In fact, the risk may be higher in patients receiving certain TKIs in a sequential manner.
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Potential mechanisms underlying VAEs in TKI-treated patients
Several different factors may contribute to the development of VAEs in patients treated with nilotinib or ponatinib (Supplemental Table S3 ). 54,66,67 Because of the relatively short time-interval between drug exposure and occurrence of VAEs, a direct effect of these TKIs on vascular and/or perivascular cells has been postulated. 54 Indeed, nilotinib may exert direct pro-atherogenic and antiangiogenic effects on endothelial cells (Supplemental Table S3 ). 54 Whereas the pro-atherogenic effect may lead to arterial stenosis, the anti-angiogenic effect of the drug may block repair mechanisms leading to recanalization and reperfusion once arterial stenosis occured. 54 It has also been described that nilotinib may cause vasospasms which may also be relevant and trigger PAOD-development.
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In addition, nilotinib exerts metabolic effects, including an increase in cholesterol and fasting glucose levels (Supplemental Table S3 
Management of VAEs in patients with CML
In patients developing VAEs during treatment with nilotinib or ponatinib, management depends on the overall situation in each case. In patients with low grade (grade I and II) PAOD, optimal therapy of PAOD and the elimination of all risk factors (smoking, obesity, diabetes mellitus, arterial hypertension, hypercholesterolemia) may lead to a stabilization of the condition, so that treatment can be continued which is important as some of these patients may have no other therapeutic options (e.g. those with BCR/ABL1 T315I). For these patients a thorough follow-up regarding cardiovascular and metabolic parameters (including vascular ultrasound investigations, ABI, cholesterol and fasting glucose levels, HbA1c) and PAOD-related risk factors (age, obesity, arterial blood pressure, smoking habits) is recommended. 31 In addition, prophylactic treatment with aspirin should be considered. Additional co-medication may also be required, depending on risk factors and comorbidities. These patients may receive antidiabetic and/or cholesterol-lowering drugs.
In patients with high grade PAOD (grade III or IV) the situation is more difficult to manage. Some of these patients may still need to be treated with nilotinib or ponatinib based on the biology (mutation-status) of their CML. In other patients, the drug should be discontinued or replaced by another TKI. In select cases with stable CMR, discontinuation of TKI-therapy may be considered. 70 For all other patients, a general recommendation is to switch to another TKI if possible. PAOD requiring interventional revascularization procedures, central (cerebral) ischemia and myocardial infarction are additional indications to switch to another TKI. In all these patients, platelet aggregation inhibitors or anticoagulation should be considered following generally accepted guidelines. In these patients it is also essential to eliminate all risk factors and to treat hyperlipidemia, diabetes mellitus and arterial hypertension early and as effective as possible (Supplemental Table   S4 ). An unresolved question is whether a slight elevation in the fasting glucose level that is quite frequently seen in nilotinib-treated patients, should already lead to early intervention with anti-diabetic therapy. At least repeated testing of glucose and HbA1c, and an oral glucose tolerance test (OGTT) seems justified; 1 3 when the fasting glucose level permanently increases to >125 mg/dL or the OGTT is clearly pathologic, anti-diabetic treatment should be considered.
How to prevent the development of VAEs in TKI-treated patients
Based on the severity of VAEs, the relatively good prognosis of CML patients even in the second-and third-line setting, and the impact of VAEs on overall morbidity and transplant-eligibility, it is of utmost importance to avoid VAEs in all CML patients, regardless of age and other factors. A first important step in prevention is patient-selection for second-and third-line TKIs. Such TKIs should be selected not only on the basis of disease-related parameters such as BCR/ABL1 mutations, but also based on patient-related variables, including comorbidities and overt risk factors for AE-development. Indeed, more and more guidelines and treatment-algorithms take patient-related factors into account, thereby fulfilling the criteria of personalized medicine.
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Based on the frequent detection of risk factors for PAOD-development in the general population (adults) in the Western World, it is important to determine the individual risk in each case using validated scores, such as the European Society of Cardiology (ESC) score. This score should indeed be applied in order to select optimal and safe TKIs for all patients with CML. Patients in whom multiple risk factors or/and a high ESC are found should not be exposed to nilotinib or ponatinib if other TKIs can be prescribed. However, even low-risk patients 1 4 according to the ESC score may develop VAEs when treated with Nilotinib or Ponatinib (P.V., personal observation). Another unfortunate aspect is that several risk factors for PAOD development are also independent risk factors for the development of pleural effusions during dasatinib-therapy (Supplemental Table   S2 ). 64, 65 Especially in elderly patients, neither nilotinib nor dasatinib may be an optimal TKI. Whether bosutinib may be a better choice for these patients remains to be determined in clinical trials. In contrast, ponatinib should not be considered as an alternative drug in these patients, unless leukemic cells express BCR/ABL1
T315I. In each case, the potential benefit of ponatinib has to be balanced against the potential AE-risk. Several other strategies may keep the risk of severe VAEs in TKI-treated CML patients to a minimum. These strategies are described in the Supplemental Appendix.
Concluding Remarks and Future Perspectives
Vascular safety has become an emerging challenge in the treatment of CML patients with second-and third-generation BCR/ABL1 TKIs. Whereas the vascular safety of imatinib is well documented, exposure to nilotinib and ponatinib is associated with an increased rate of arterial occlusive events. Therefore, it is of great importance to consider the overall risk profile before starting therapy and to include co-morbidities and risk factors for AOD development in novel treatment algorithms. It is also important to monitor metabolic and cardio-vascular ---------------------------------------------------------------------------------------------------------------- 
